515 related articles for article (PubMed ID: 23524130)
1. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
[TBL] [Abstract][Full Text] [Related]
2. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.
Butt AA; Yan P; Shaikh OS; Freiberg MS; Lo Re V; Justice AC; Sherman KE;
J Viral Hepat; 2015 Sep; 22(9):691-700. PubMed ID: 25524834
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
4. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
Faisal N; Yoshida EM; Bilodeau M; Wong P; Ma M; Burak KW; Al-Judaibi B; Renner EL; Lilly LB
Ann Hepatol; 2014; 13(5):525-32. PubMed ID: 25152985
[TBL] [Abstract][Full Text] [Related]
5. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.
Beste LA; Green PK; Ioannou GN
Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):123-9. PubMed ID: 25503739
[TBL] [Abstract][Full Text] [Related]
6. Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir.
Vo KP; Vutien P; Akiyama MJ; Vu VD; Ha NB; Piotrowski JI; Wantuck J; Roytman MM; Tsai N; Cheung R; Li J; Nguyen MH
Dig Dis Sci; 2015 Apr; 60(4):1045-51. PubMed ID: 25821099
[TBL] [Abstract][Full Text] [Related]
7. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
Cammà C; Petta S; Cabibbo G; Ruggeri M; Enea M; Bruno R; Capursi V; Gasbarrini A; Alberti A; Craxì A;
J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
[TBL] [Abstract][Full Text] [Related]
9. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.
Salmerón J; Vinaixa C; Berenguer R; Pascasio JM; Sánchez Ruano JJ; Serra MÁ; Gila A; Diago M; Romero-Gómez M; Navarro JM; Testillano M; Fernández C; Espinosa D; Carmona I; Pons JA; Jorquera F; Rodriguez FJ; Pérez R; Montero JL; Granados R; Fernández M; Martín AB; Muñoz de Rueda P; Quiles R;
World J Gastroenterol; 2015 Aug; 21(30):9163-74. PubMed ID: 26290644
[TBL] [Abstract][Full Text] [Related]
11. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
Miailhes P; Gilbert C; Lacombe K; Arends JE; Puoti M; Rockstroh JK; Sogni P; Fontaine H; Rosenthal E; Winnock M; Loko MA; Wittkop L; Dabis F; Salmon D;
Liver Int; 2015 Sep; 35(9):2090-9. PubMed ID: 25650873
[TBL] [Abstract][Full Text] [Related]
12. Direct-acting antiviral (DAA) actions in treatment-naïve patients.
Hézode C
Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S52-8. PubMed ID: 22248695
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting.
Price JC; Murphy RC; Shvachko VA; Pauly MP; Manos MM
Dig Dis Sci; 2014 Dec; 59(12):3043-52. PubMed ID: 25102983
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.
Werner CR; Franz C; Egetemeyr DP; Janke-Maier P; Malek NP; Lauer UM; Berg CP
J Viral Hepat; 2014 May; 21(5):333-40. PubMed ID: 24716636
[TBL] [Abstract][Full Text] [Related]
17. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans.
Ioannou GN; Beste LA; Green PK
Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1371-80. PubMed ID: 24361415
[TBL] [Abstract][Full Text] [Related]
18. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
[TBL] [Abstract][Full Text] [Related]
19. Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort.
Mauss S; Böker K; Buggisch P; Christensen S; Hofmann WP; Schott E; Pfeiffer-Vornkahl H; Alshuth U; Hüppe D
Z Gastroenterol; 2015 Jul; 53(7):644-54. PubMed ID: 26167694
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort.
Backus LI; Belperio PS; Shahoumian TA; Cheung R; Mole LA
Aliment Pharmacol Ther; 2014 Jan; 39(1):93-103. PubMed ID: 24206566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
